← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Amicus Therapeutics, Inc. (FOLD) 10-Year Financial Performance & Capital Metrics

FOLD •
HealthcareBiotechnologyCommercial Rare Disease Biopharma
AboutAmicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.Show more
  • Revenue $528M +32.3%
  • EBITDA $33M +148.2%
  • Net Income -$56M +63.0%
  • EPS (Diluted) -0.18 +64.7%
  • Gross Margin 89.98% -0.7%
  • EBITDA Margin 6.33% +136.4%
  • Operating Margin 4.71% +124.4%
  • Net Margin -10.62% +72.0%
  • ROE -31.68% +70.4%
  • ROIC 4.77% +132.3%
  • Debt/Equity 2.29 -17.7%
  • Interest Coverage 0.50 +132.6%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Momentum leader: RS Rating 92 (top 8%)
  • ✓Strong 5Y sales CAGR of 23.7%
  • ✓Trading near 52-week high

✗Weaknesses

  • ✗High debt to equity ratio of 2.3x
  • ✗Negative free cash flow
  • ✗Expensive at 22.5x book value

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y83.45%
5Y23.72%
3Y20.03%
TTM21.28%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM86.57%

EPS CAGR

10Y-
5Y-
3Y-
TTM87%

ROCE

10Y Avg-30.17%
5Y Avg-20.23%
3Y Avg-13.5%
Latest3.99%

Peer Comparison

Commercial Rare Disease Biopharma
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
CORTCorcept Therapeutics Incorporated3.78B35.7043.5412.79%13.01%15.3%3.75%0.01
BMRNBioMarin Pharmaceutical Inc.11.86B61.7334.2910.83%5.73%6.11%0.10
VRTXVertex Pharmaceuticals Incorporated126.19B496.8332.438.9%31.35%21.22%2.53%0.20
CPRXCatalyst Pharmaceuticals, Inc.2.83B23.0813.7419.78%36.39%22.46%7.38%0.00
HRMYHarmony Biosciences Holdings, Inc.1.65B28.5410.5321.51%18.27%18.24%21.12%0.02
PTCTPTC Therapeutics, Inc.5.45B68.198.76114.51%42.25%
BCRXBioCryst Pharmaceuticals, Inc.1.86B8.757.2394.1%30.16%18.63%
RAREUltragenyx Pharmaceutical Inc.2.26B23.39-3.7229.01%-91.95%-35.88%0.15

Compare FOLD vs Peers

Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.

vs AGIO

Compare head-to-head with Agios Pharmaceuticals, Inc.

vs VRTX

Compare head-to-head with Vertex Pharmaceuticals Incorporated

Compare Top 5

vs AGIO, VRTX, ASND, BBIO

Profit & Loss

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+04.96M36.93M91.25M182.24M260.89M305.51M329.23M399.36M528.29M
Revenue Growth %-100%-644.86%147.08%99.72%43.16%17.11%7.76%21.3%32.29%
Cost of Goods Sold+1.83M833K6.24M14.4M21.96M31.04M34.47M38.6M37.33M52.94M
COGS % of Revenue-16.8%16.89%15.79%12.05%11.9%11.28%11.72%9.35%10.02%
Gross Profit+-1.83M4.13M30.69M76.84M160.27M229.84M271.05M290.63M362.03M475.35M
Gross Margin %-83.2%83.11%84.21%87.95%88.1%88.72%88.28%90.65%89.98%
Gross Profit Growth %-249.75%325.04%644.1%150.35%108.58%43.41%17.93%7.23%24.57%31.3%
Operating Expenses+126.05M179.19M241.57M402.32M464.31M476.84M477.48M502.75M439.24M450.48M
OpEx % of Revenue-3614.08%654.14%440.92%254.78%182.78%156.29%152.7%109.99%85.27%
Selling, General & Admin47.27M71.15M88.67M127.2M169.86M156.41M192.71M213.04M275.27M323.38M
SG&A % of Revenue-1435.07%240.11%139.4%93.21%59.95%63.08%64.71%68.93%61.21%
Research & Development76.94M104.79M149.31M270.9M286.38M308.44M272.05M276.68M152.38M109.36M
R&D % of Revenue-2113.61%404.31%296.9%157.15%118.23%89.05%84.04%38.16%20.7%
Other Operating Expenses-80K-4.79M6.01M-5.63M8.07M11.99M12.72M13.04M11.59M17.73M
Operating Income+-130.44M-181.89M-441.99M-328.78M-304.04M-247M-206.43M-212.12M-77.21M24.88M
Operating Margin %--3668.62%-1196.82%-360.32%-166.84%-94.68%-67.57%-64.43%-19.33%4.71%
Operating Income Growth %-89.86%-39.45%-143%25.61%7.52%18.76%16.42%-2.75%63.6%132.22%
EBITDA+-128.6M-178.65M-438.39M-324.56M-299.26M-238.15M-200.22M-206.78M-69.34M33.42M
EBITDA Margin %--3603.23%-1187.09%-355.7%-164.22%-91.29%-65.54%-62.81%-17.36%6.33%
EBITDA Growth %-91.51%-38.91%-145.39%25.97%7.79%20.42%15.93%-3.27%66.47%148.2%
D&A (Non-Cash Add-back)1.83M3.24M3.59M4.22M4.78M8.85M6.21M5.34M7.87M8.55M
EBIT-130.54M-198.38M-431.88M-326.69M-337.04M-251.83M-209.08M-204.92M-99.95M20.84M
Net Interest Income+-649K-3.8M-13.14M-11.94M-8.62M-19.2M-31.96M-34.09M-43.07M-44.19M
Interest Income929K1.6M4.1M10.46M10.25M3.23M509K3.02M7.08M5.41M
Interest Expense1.58M5.4M17.24M22.4M18.87M22.43M32.47M37.12M50.15M49.6M
Other Income/Expense-6.07M-21.89M-7.14M-23.61M-51.87M-27.26M-35.12M-29.92M-72.89M-53.63M
Pretax Income+-132.12M-203.78M-449.12M-349.09M-355.91M-274.25M-241.55M-242.04M-150.1M-28.76M
Pretax Margin %--4110.15%-1216.14%-382.58%-195.3%-105.12%-79.06%-73.52%-37.59%-5.44%
Income Tax+1.5M-3.74M-165.12M-94K478K2.6M8.91M-5.47M1.48M27.35M
Effective Tax Rate %100%98.17%63.24%99.97%100.13%100.95%103.69%97.74%100.99%195.11%
Net Income+-132.12M-200.04M-284M-349M-356.39M-276.85M-250.46M-236.57M-151.58M-56.11M
Net Margin %--4034.73%-769.03%-382.48%-195.56%-106.12%-81.98%-71.85%-37.96%-10.62%
Net Income Growth %-91.68%-51.41%-41.97%-22.88%-2.12%22.32%9.53%5.55%35.92%62.99%
Net Income (Continuing)-132.12M-200.04M-284M-349M-356.39M-276.85M-250.46M-236.57M-151.58M-56.11M
Discontinued Operations0000000000
Minority Interest0000000000
EPS (Diluted)+-1.20-1.49-1.85-1.88-1.48-1.07-0.92-0.82-0.51-0.18
EPS Growth %-29.03%-24.17%-24.16%-1.62%21.28%27.7%14.02%10.87%37.8%64.71%
EPS (Basic)-1.20-1.49-1.85-1.88-1.48-1.07-0.92-0.82-0.51-0.18
Diluted Shares Outstanding109.92M134.4M153.36M185.79M240.42M258.87M271.42M289.06M295.16M304.38M
Basic Shares Outstanding109.92M134.4M153.36M185.79M240.42M258.87M271.42M289.06M295.16M304.38M
Dividend Payout Ratio----------

Balance Sheet

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+216.6M340.06M391.96M551.1M520.07M579.47M596.83M423.82M483.06M504.74M
Cash & Short-Term Investments214.03M330.35M358.56M504.15M452.74M483.27M482.5M293.6M286.2M249.95M
Cash Only69.48M187.03M49.06M79.75M142.84M163.24M245.2M148.81M246.99M213.75M
Short-Term Investments144.55M143.32M309.5M424.4M309.9M320.03M237.3M144.78M39.21M36.19M
Accounts Receivable01.3M9.46M21.96M33.28M46.92M52.67M66.2M87.63M101.1M
Days Sales Outstanding-9693.5487.8566.6665.6562.9373.3980.0969.85
Inventory03.42M4.62M8.39M14.04M19.56M26.82M23.82M59.7M118.78M
Days Inventory Outstanding-1.5K270.59212.6233.35229.93284.01225.21583.75818.91
Other Current Assets2.57M4.99M19.32M16.59M00040.21M49.53M34.91M
Total Non-Current Assets+691.78M696.78M235.06M238.85M330.13M307.05M308.31M300.35M294.82M280.3M
Property, Plant & Equipment6.18M9.82M9.06M11.38M81.02M67.16M63.08M60.31M57.98M51.66M
Fixed Asset Turnover-0.51x4.08x8.02x2.25x3.88x4.84x5.46x6.89x10.23x
Goodwill197.8M197.8M197.8M197.8M197.8M197.8M197.8M197.8M197.8M197.8M
Intangible Assets486.7M486.7M23M23M23M23M23M23M20.49M17.2M
Long-Term Investments0-173.77M-6.46M-6.46M000000
Other Non-Current Assets1.11M2.47M5.2M6.68M28.32M19.09M24.43M19.24M18.55M13.64M
Total Assets+908.38M1.04B627.02M789.95M850.21M886.52M905.14M724.17M777.88M785.03M
Asset Turnover-0.00x0.06x0.12x0.21x0.29x0.34x0.45x0.51x0.67x
Asset Growth %332.63%14.14%-39.53%25.98%7.63%4.27%2.1%-19.99%7.42%0.92%
Total Current Liabilities+73.62M110.96M70.04M86.13M128.81M129.68M145.97M139.02M167.69M148.7M
Accounts Payable16.48M12.9M7.87M6.61M21.72M17.06M21.51M15.41M15.12M12.95M
Days Payables Outstanding3.28K5.65K460.46167.4360.99200.62227.83145.75147.8589.26
Short-Term Debt0000000000
Deferred Revenue (Current)069.4M7.75M5.5M000000
Other Current Liabilities50.94M23.8M30.82M32.06M31.18M27.12M28.46M33.17M48.68M41.23M
Current Ratio2.94x3.06x5.60x6.40x4.04x4.47x4.09x3.05x2.88x3.39x
Quick Ratio2.94x3.03x5.53x6.30x3.93x4.32x3.90x2.88x2.52x2.60x
Cash Conversion Cycle--4.06K-96.34133.06-60.9994.96119.11152.85515.99799.5
Total Non-Current Liabilities+486.93M565.74M204.13M360.91M244.97M470.46M451.8M462.1M450.02M442.29M
Long-Term Debt41.6M154.46M164.17M321.74M149.5M389.25M389.36M391.99M387.86M390.11M
Capital Lease Obligations000053.53M45.6M43.36M51.58M48.88M45.08M
Deferred Tax Liabilities176.22M173.77M6.46M6.46M5.05M4.9M4.93M4.94M00
Other Non-Current Liabilities269.11M237.5M33.5M32.71M36.88M30.71M14.15M13.6M13.28M7.1M
Total Liabilities560.55M676.69M274.17M447.04M373.78M600.14M597.77M601.12M617.71M590.99M
Total Debt+41.6M154.46M164.47M321.74M210.22M441.73M440.13M452.12M445.06M443.64M
Net Debt-27.88M-32.56M115.41M241.99M67.39M278.49M194.93M303.31M198.06M229.89M
Debt / Equity0.12x0.43x0.47x0.94x0.44x1.54x1.43x3.67x2.78x2.29x
Debt / EBITDA---------13.27x
Net Debt / EBITDA---------6.88x
Interest Coverage-82.66x-33.70x-25.64x-14.68x-16.11x-11.01x-6.36x-5.71x-1.54x0.50x
Total Equity+347.83M360.15M352.85M342.91M476.43M286.38M307.37M123.05M160.17M194.04M
Equity Growth %184.69%3.54%-2.03%-2.82%38.94%-39.89%7.33%-59.97%30.17%21.15%
Book Value per Share3.162.682.301.851.981.111.130.430.540.64
Total Shareholders' Equity347.83M360.15M352.85M342.91M476.43M286.38M307.37M123.05M160.17M194.04M
Common Stock1.31M1.48M1.72M1.94M2.6M2.65M2.81M2.81M2.92M2.94M
Retained Earnings-579.57M-779.61M-1.06B-1.41B-1.77B-2.05B-2.3B-2.53B-2.68B-2.74B
Treasury Stock0000000000
Accumulated OCI-115K2.05M-2.1M68K2.83M8.23M4.98M-12.11M5.24M5.09M
Minority Interest0000000000

Cash Flow

Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-100.14M-150.53M-215.49M-299.95M-250.42M-233.29M-202.49M-166.57M-69.09M-33.89M
Operating CF Margin %--3036.18%-583.5%-328.74%-137.41%-89.42%-66.28%-50.59%-17.3%-6.42%
Operating CF Growth %-93.81%-50.32%-43.15%-39.2%16.52%6.84%13.2%17.74%58.52%50.95%
Net Income-132.12M-200.04M-284M-349M-356.39M-276.85M-250.46M-236.57M-151.58M-56.11M
Depreciation & Amortization1.83M3.24M3.59M4.22M4.78M8.85M6.21M5.34M7.87M8.55M
Stock-Based Compensation9.97M17.5M23.1M29.26M44.43M49.15M57.84M76.51M86.08M84.91M
Deferred Taxes952K-3.74M-167.31M6.01M-1.42M-155K34K9K-4.94M0
Other Non-Cash Items4.88M31.37M234.91M14.28M46.57M17.78M2.47M28.01M41.47M27.71M
Working Capital Changes14.34M1.14M-25.79M-4.73M11.61M-32.06M-18.59M-39.88M-47.99M-98.94M
Change in Receivables0-1.42M-7.72M-13.29M-11.11M-11.22M-8.19M-17.33M-20.11M-19.48M
Change in Inventory0-3.65M-897K-4.21M-5.11M-4.64M-7.79M-5.34M-44.61M-73.65M
Change in Payables15.47M7.13M12.56M17.11M46.74M-10.61M7.43M-6.38M49.2M-16.52M
Cash from Investing+-145.34M-4.51M-171.24M-121.2M95.15M-13.58M78.76M92.32M98.06M-560K
Capital Expenditures-4.82M-5.95M-4.53M-6.31M-20.01M-3.23M-3.88M-3.77M-7.44M-3.55M
CapEx % of Revenue-120.03%12.26%6.91%10.98%1.24%1.27%1.14%1.86%0.67%
Acquisitions-141.06M006.31M0003.41M00
Investments----------
Other Investing534K1.44M-166.72M-6.31M000000
Cash from Financing+290.89M272.71M247.43M450.77M217.5M262.86M212.07M-7.46M61.68M5.12M
Debt Issued (Net)34.71M192.34M-308K146.26M-420K230.6M-479K-283K-20.96M-97K
Equity Issued (Net)1000K1000K1000K1000K1000K01000K-1000K1000K1000K
Dividends Paid0000000000
Share Repurchases-2.04M-1.28M-1.6M-2.83M000-11.49M00
Other Financing13.14M-16.7M4.71M9.93M28.93M32.25M12.8M0-20.57M-22.02M
Net Change in Cash45.41M117.54M-137.97M31.14M63.97M19.82M83.29M-96.34M96.96M-33.36M
Free Cash Flow+-104.96M-156.49M-220.01M-306.26M-270.43M-236.52M-206.38M-170.34M-76.53M-37.44M
FCF Margin %--3156.21%-595.75%-335.65%-148.39%-90.66%-67.55%-51.74%-19.16%-7.09%
FCF Growth %-102.2%-49.1%-40.6%-39.2%11.7%12.54%12.74%17.46%55.07%51.07%
FCF per Share-0.95-1.16-1.43-1.65-1.12-0.91-0.76-0.59-0.26-0.12
FCF Conversion (FCF/Net Income)0.76x0.75x0.76x0.86x0.70x0.84x0.81x0.70x0.46x0.60x
Interest Paid0007.5M16.97M24.68M30.47M34.36M36.09M58.96M
Taxes Paid0001.06M691K10.37M20.03M1.07M8.53M8.21M

Key Ratios

Metric2015201620172018201920202021202220232024
Return on Equity (ROE)-56.22%-56.51%-79.66%-100.32%-86.99%-72.59%-84.37%-109.93%-107.04%-31.68%
Return on Invested Capital (ROIC)-45.25%-42.13%-83.3%-46.83%-40.4%-33.42%-29.02%-34.26%-14.76%4.77%
Gross Margin-83.2%83.11%84.21%87.95%88.1%88.72%88.28%90.65%89.98%
Net Margin--4034.73%-769.03%-382.48%-195.56%-106.12%-81.98%-71.85%-37.96%-10.62%
Debt / Equity0.12x0.43x0.47x0.94x0.44x1.54x1.43x3.67x2.78x2.29x
Interest Coverage-82.66x-33.70x-25.64x-14.68x-16.11x-11.01x-6.36x-5.71x-1.54x0.50x
FCF Conversion0.76x0.75x0.76x0.86x0.70x0.84x0.81x0.70x0.46x0.60x
Revenue Growth-100%-644.86%147.08%99.72%43.16%17.11%7.76%21.3%32.29%

Deep Dive Analysis

Explore detailed financial history, valuation models, and returns analysis

Valuation Overview

DCF models, peer multiples & analyst estimates

Total Return Calculator

Historical returns with dividends reinvested

Dividend History

Yield, growth, payout safety & DRIP calculator

Earnings History

EPS trends, net income & profitability analysis

Price History

Long-term charts & historical price data

Revenue History

Sales growth patterns & revenue breakdown

Financial Ratios

30 years of valuation, profitability & efficiency metrics

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.